Relapsed and/or Refractory Mantle cell Lymphoma: What Role for Temsirolimus?
Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis o...
Main Authors: | Sebastian Kirschey, Susanne Wagner, Georg Hess |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S7327 |
Similar Items
-
Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
by: Sebastian Kirschey, et al.
Published: (2012-03-01) -
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
by: S Galimberti, et al.
Published: (2010-06-01) -
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
by: Georg Hess, et al.
Published: (2020-06-01) -
Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
by: Enver Aydilek, et al.
Published: (2023-09-01) -
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
by: Madelyn Burkart, et al.
Published: (2022-03-01)